Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548587 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT00548587 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 600 participants.
The verdict
NCT00548587, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
Interventions
- DRUG Placebo
- DRUG E5555
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548587
The ClinicalTrials.gov registry entry for NCT00548587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00548587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548587 about?
NCT00548587 is a clinical study titled "Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome". This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
What is the current status of trial NCT00548587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2007-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00548587?
The interventions under investigation include: Placebo (DRUG), E5555 (DRUG).
Who is sponsoring clinical trial NCT00548587?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.